Jump to:
Philip Wu joined the New York office of Ropes & Gray in 2022 and works in the corporate department.
Philip attended Northwestern University Pritzker School of Law, where he served as a notes editor for the Journal of Technology and Intellectual Property. Additionally, he volunteered with Asian Law Alliance in San Jose, California and interned with a regulatory compliance start up.
Philip currently serves as a member of Northwestern University Pritzker School of Law’s Young Alumni Leadership Council.
Prior to law school, Philip worked and taught in the golf industry.
Experience
- Represented Trinseo plc in connection with a transaction support agreement to, among other things, (i) redeem its existing $115 million 2025 Senior Notes with the proceeds of a new super holdco term loan, (ii) enter into a new $300 million super-priority revolving credit facility and (iii) exchange at least $330 million of 2029 Senior Notes for new 2029 Second Lien Senior Secured Notes at a discount to par, providing at least $49 million of discount capture.
- Represented Becton, Dickinson and Company in its $4.2 billion acquisition of the Critical Care business of Edwards Lifesciences Corporation.
- Represented Areteia Therapeutics, Inc. in its $75 million expansion of its Series A financing.
- Represented the underwriters in connection with HAT Holdings I LLC and HAT Holdings II LLC (each a subsidiary of HA Sustainable Infrastructure Capital, Inc.) offering $550 million aggregate principal proceeds of 8.00% Green Senior Unsecured Notes due 2027.
- Represented Paratek Pharmaceuticals, a biopharmaceutical company, in its $462 million take-private acquisition by Gurnet Point Capital and Novo Holdings.
- Represented Trinseo plc, a leading global specialty material solutions provider, and certain of its affiliates, in connection with a $1.1 billion innovative financing transaction addressing the Company’s near term maturities in September 2023.
- Represented Jounce Therapeutics, a clinical-stage immuno-oncology company, in its acquisition by Concentra Biosciences for $100 million plus contingent value rights.
- Ongoing representation of public company clients in connection with securities law and corporate governance matters.